Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: CA76375-01
Agency Tracking Number: 39143
Amount: $99,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Solicitation Year: N/A
Award Year: 1997
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
570 MONTVIEW BLVD, Denver, CO, 80209
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 () -
Business Contact
Phone: (303) 394-3123
Research Institution
"Creatv MicroTech proposes to develop high precision x-ray anti-scatter grids for medical imaging to improve image contrast of diseased tissue by reducing the detection of scattered x-rays produced by the imaging object. Some of the potential properties of the proposed anti-scatter grid are: (i) the grid pattern is two-dimensional, (ii) the vertical air-core opening is focused to a point x-ray source, (iii) the grid patterns can be made precisely, (iv) the grid patterns are reproducible with precision and (v) the grid ratio of grid (wall height versus grid opening size) is not restricted. In Phase I, research will concentrate on (i) evaluation of the grids for performance, (iii) evaluation of all the available approaches of making a focused grid and the associated fabrication issues. In Phase II, research will concentrate on the fabrication and testing of the focused grids." $ = TOTAL AWARD AMTS & NOT LIMITED TO PORTION OF PROJECT RELATED TO SUBJECT OF SEARCH SUBPROJECT $ = TOTAL AWARD AMOUNT DIVIDED BY NUMBER OF SUBPROJECTS SOURCE: CRISP FORMAT F FY 97 LAST UPDATE 04-07-98 1QUERY 1536 ID SEARCH 06/01/98 PAGE 212 --PROJECT NUMBER......1 R43 CA76794-01 INVESTIGATOR NAME/ADDRESS FY 97 RICE, GLENN C IRG/INTRAMURAL UNIT..ZRG2 CYTOKINE NETWORKS, INC AWARD AMOUNT......... $99,343 101 ELLIOTT AVE, WEST SEATTLE, WA 98119 PERFORMING ORGANIZATION: CYTOKINE NETWORK, INC. TITLE DEVELOPMENT OF FIBROCYTES FOR ANTICANCER THERAPY ABSTRACT: Recent studies have identified a novel population of blood-borne cells, termed fibrocytes, that have a distinct cell surface phenotype (CD34+/collagen +/CD13+/CD45+), and express each of the known surface components that are required for antigen presentation, including class I and class ll MHC molecules (HLA-DP, -DQ, and -DR), the co-stimulatory molecules CD80 and CD86, and the adhesion molecules CD11a, CD54, and CD58. Human fibrocytes induce antigen presenting cell (APC) -dependent T cell proliferation and this proliferative activity is as high as that induced by purified dendritic cells. In their present form, fibrocytes are significantly easier to isolate and culture than are dendritic cells. Importantly, mouse fibrocytes pulsed in vitro with the HIV-proteins p24 or gp 120 and delivered to a site of cutaneous injury migrate to proximal lymph nodes and specifically prime naive T cells. This project will Optimize growth and culture conditions for ex vivo human fibrocyte growth, antigen display, and induction of T-cell responses measured both in vitro and in vivo. It is expected that positive data from these studies will provide the basis for validated GLP methods required for initiation of clinical trials involving autologous fibrocytes for anti-cancer and ultimately anti-HIV therapies.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government